• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

群体药效动力学实验中离散数据反应的群体 Fisher 信息矩阵和最优设计。

Population Fisher information matrix and optimal design of discrete data responses in population pharmacodynamic experiments.

机构信息

Centre for Applied Pharmacokinetic Research, The University of Manchester, Oxford Road, Manchester, UK.

出版信息

J Pharmacokinet Pharmacodyn. 2011 Aug;38(4):449-69. doi: 10.1007/s10928-011-9203-7. Epub 2011 Jun 10.

DOI:10.1007/s10928-011-9203-7
PMID:21660504
Abstract

In the recent years, interest in the application of experimental design theory to population pharmacokinetic (PK) and pharmacodynamic (PD) experiments has increased. The aim is to improve the efficiency and the precision with which parameters are estimated during data analysis and sometimes to increase the power and reduce the sample size required for hypothesis testing. The population Fisher information matrix (PFIM) has been described for uniresponse and multiresponse population PK experiments for design evaluation and optimisation. Despite these developments and availability of tools for optimal design of population PK and PD experiments much of the effort has been focused on repeated continuous variable measurements with less work being done on repeated discrete type measurements. Discrete data arise mainly in PDs e.g. ordinal, nominal, dichotomous or count measurements. This paper implements expressions for the PFIM for repeated ordinal, dichotomous and count measurements based on analysis by a mixed-effects modelling technique. Three simulation studies were used to investigate the performance of the expressions. Example 1 is based on repeated dichotomous measurements, Example 2 is based on repeated count measurements and Example 3 is based on repeated ordinal measurements. Data simulated in MATLAB were analysed using NONMEM (Laplace method) and the glmmML package in R (Laplace and adaptive Gauss-Hermite quadrature methods). The results obtained for Examples 1 and 2 showed good agreement between the relative standard errors obtained using the PFIM and simulations. The results obtained for Example 3 showed the importance of sampling at the most informative time points. Implementation of these expressions will provide the opportunity for efficient design of population PD experiments that involve discrete type data through design evaluation and optimisation.

摘要

近年来,人们对将实验设计理论应用于群体药代动力学(PK)和药效动力学(PD)实验的兴趣日益增加。其目的是提高数据分析过程中参数估计的效率和精度,有时还可以提高假设检验的功效并减少所需的样本量。群体 Fisher 信息矩阵(PFIM)已被用于单反应和多反应群体 PK 实验的设计评估和优化。尽管已经有了这些发展和用于优化群体 PK 和 PD 实验设计的工具,但大部分工作都集中在重复的连续变量测量上,而对重复的离散型测量的研究较少。离散数据主要出现在 PD 中,例如有序、名义、二分类或计数测量。本文基于混合效应建模技术的分析,实现了重复有序、二分类和计数测量的 PFIM 表达式。使用了三个模拟研究来研究这些表达式的性能。实例 1 基于重复的二分类测量,实例 2 基于重复的计数测量,实例 3 基于重复的有序测量。在 MATLAB 中模拟的数据使用 NONMEM(拉普拉斯方法)和 R 中的 glmmML 包(拉普拉斯和自适应高斯-赫尔墨特求积方法)进行分析。实例 1 和 2 的结果表明,使用 PFIM 和模拟获得的相对标准误差之间具有良好的一致性。实例 3 的结果表明,在最具信息性的时间点进行采样的重要性。这些表达式的实现将为涉及离散型数据的群体 PD 实验的有效设计提供机会,可通过设计评估和优化来实现。

相似文献

1
Population Fisher information matrix and optimal design of discrete data responses in population pharmacodynamic experiments.群体药效动力学实验中离散数据反应的群体 Fisher 信息矩阵和最优设计。
J Pharmacokinet Pharmacodyn. 2011 Aug;38(4):449-69. doi: 10.1007/s10928-011-9203-7. Epub 2011 Jun 10.
2
Sample size calculations for population pharmacodynamic experiments involving repeated dichotomous observations.涉及重复二分观测的群体药效学实验的样本量计算
J Biopharm Stat. 2008;18(6):1212-27. doi: 10.1080/10543400802375845.
3
Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.使用 SIMCYP(®) 模拟作为先验信息确定药物及其代谢物的最佳采样时间。
Clin Pharmacokinet. 2013 Jan;52(1):43-57. doi: 10.1007/s40262-012-0022-9.
4
Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes.基于生理药代动力学(PBPK)模型和最优多响应采样时间设计的药物相互作用预测:应用于咪达唑仑和一种I期化合物。第1部分:使用PopDes比较单响应和多响应设计
J Pharmacokinet Pharmacodyn. 2008 Dec;35(6):635-59. doi: 10.1007/s10928-008-9104-6. Epub 2009 Jan 7.
5
Sample size/power calculations for population pharmacodynamic experiments involving repeated-count measurements.涉及重复计数测量的群体药效学实验的样本量/效能计算
J Biopharm Stat. 2010 Sep;20(5):1026-42. doi: 10.1080/10543401003619205.
6
PFIM 4.0, an extended R program for design evaluation and optimization in nonlinear mixed-effect models.PFIM 4.0,一个用于非线性混合效应模型设计评估和优化的扩展 R 程序。
Comput Methods Programs Biomed. 2018 Mar;156:217-229. doi: 10.1016/j.cmpb.2018.01.008. Epub 2018 Jan 11.
7
Design evaluation and optimisation in crossover pharmacokinetic studies analysed by nonlinear mixed effects models.交叉药代动力学研究中通过非线性混合效应模型进行的设计评价与优化。
Stat Med. 2012 May 20;31(11-12):1043-58. doi: 10.1002/sim.4390. Epub 2011 Oct 3.
8
Incorporating correlation in interindividual variability for the optimal design of multiresponse pharmacokinetic experiments.在多反应药代动力学实验的优化设计中纳入个体间变异性的相关性。
J Biopharm Stat. 2008;18(2):342-58. doi: 10.1080/10543400701697208.
9
Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0.多响应非线性混合效应模型中的设计评估与优化:PFIM 3.0。
Comput Methods Programs Biomed. 2010 Apr;98(1):55-65. doi: 10.1016/j.cmpb.2009.09.012. Epub 2009 Nov 4.
10
Sample size/power calculations for repeated ordinal measurements in population pharmacodynamic experiments.群体药效动力学试验中重复有序测量的样本量/功效计算。
J Pharmacokinet Pharmacodyn. 2010 Feb;37(1):67-83. doi: 10.1007/s10928-009-9144-6. Epub 2009 Dec 5.

引用本文的文献

1
Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014).药物研发期间剂量和给药方案确定的先进方法:欧洲药品管理局/欧洲制药工业协会联合会剂量确定研讨会总结(2014年12月4 - 5日,伦敦)
CPT Pharmacometrics Syst Pharmacol. 2017 Jul;6(7):418-429. doi: 10.1002/psp4.12196. Epub 2017 Jul 19.
2
Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model.基于二分马尔可夫链混合效应睡眠模型的最佳临床试验设计。
J Pharmacokinet Pharmacodyn. 2014 Dec;41(6):639-54. doi: 10.1007/s10928-014-9391-z. Epub 2014 Oct 12.
3

本文引用的文献

1
Sample size/power calculations for population pharmacodynamic experiments involving repeated-count measurements.涉及重复计数测量的群体药效学实验的样本量/效能计算
J Biopharm Stat. 2010 Sep;20(5):1026-42. doi: 10.1080/10543401003619205.
2
Sample size/power calculations for repeated ordinal measurements in population pharmacodynamic experiments.群体药效动力学试验中重复有序测量的样本量/功效计算。
J Pharmacokinet Pharmacodyn. 2010 Feb;37(1):67-83. doi: 10.1007/s10928-009-9144-6. Epub 2009 Dec 5.
3
Performance in population models for count data, part I: maximum likelihood approximations.
Pharmacokinetic and pharmacodynamic analysis comparing diverse effects of detomidine, medetomidine, and dexmedetomidine in the horse: a population analysis.
比较右美托咪定、美托咪定和地托咪定对马的不同作用的药代动力学和药效学分析:一项群体分析
J Vet Pharmacol Ther. 2015 Feb;38(1):24-34. doi: 10.1111/jvp.12139. Epub 2014 Jul 29.
4
D optimal designs for three Poisson dose-response models.三种泊松剂量反应模型的 D 最优设计。
J Pharmacokinet Pharmacodyn. 2013 Apr;40(2):201-11. doi: 10.1007/s10928-013-9300-x. Epub 2013 Feb 19.
5
Optimal designs for composed models in pharmacokinetic-pharmacodynamic experiments.组合模型在药代动力学-药效学实验中的最优设计。
J Pharmacokinet Pharmacodyn. 2012 Jun;39(3):295-311. doi: 10.1007/s10928-012-9251-7. Epub 2012 May 22.
计数数据总体模型中的性能,第一部分:最大似然近似。
J Pharmacokinet Pharmacodyn. 2009 Aug;36(4):353-66. doi: 10.1007/s10928-009-9126-8. Epub 2009 Aug 4.
4
Fisher information matrix for nonlinear mixed effects multiple response models: evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model.非线性混合效应多响应模型的费希尔信息矩阵:使用药代动力学/药效学模型评估一阶线性化的适用性
Stat Med. 2009 Jun 30;28(14):1940-56. doi: 10.1002/sim.3573.
5
An effective approach for obtaining optimal sampling windows for population pharmacokinetic experiments.一种为群体药代动力学实验获取最佳采样窗口的有效方法。
J Biopharm Stat. 2009;19(1):174-89. doi: 10.1080/10543400802536131.
6
Application of optimal design methodologies in clinical pharmacology experiments.最优设计方法在临床药理学实验中的应用。
Pharm Stat. 2009 Jul-Sep;8(3):239-52. doi: 10.1002/pst.354.
7
Sample size calculations for population pharmacodynamic experiments involving repeated dichotomous observations.涉及重复二分观测的群体药效学实验的样本量计算
J Biopharm Stat. 2008;18(6):1212-27. doi: 10.1080/10543400802375845.
8
Optimisation of sampling windows design for population pharmacokinetic experiments.
J Pharmacokinet Pharmacodyn. 2008 Aug;35(4):465-82. doi: 10.1007/s10928-008-9097-1. Epub 2008 Sep 9.
9
Incorporating correlation in interindividual variability for the optimal design of multiresponse pharmacokinetic experiments.在多反应药代动力学实验的优化设计中纳入个体间变异性的相关性。
J Biopharm Stat. 2008;18(2):342-58. doi: 10.1080/10543400701697208.
10
Design in nonlinear mixed effects models: optimization using the Fedorov-Wynn algorithm and power of the Wald test for binary covariates.非线性混合效应模型中的设计:使用费多罗夫 - 韦恩算法进行优化以及二元协变量的Wald检验功效
Stat Med. 2007 Dec 10;26(28):5162-79. doi: 10.1002/sim.2910.